fluoxetine has been researched along with Dysthymia in 21 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine." | 9.17 | L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013) |
| "Although some significant psychomotor changes were observed in a subgroup of clinically responsive dysthymic patients, the overall results of this small, nonrandomized, open-label study do not suggest a beneficial psychomotor effect associated with short-term fluoxetine treatment of dysthymia." | 9.14 | Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study. ( Maas, YJ; Sabbe, BG; Schrijvers, D, 2009) |
| " In the intent-to-treat sample, random regression analyses of the Hamilton Rating Scale for Depression (Ham-D; 24-item) and Cornell Dysthymia Rating Scale (CDRS) scores at each visit produced significant time x treatment group interactions favoring the fluoxetine group." | 9.11 | Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005) |
| "We studied the effects of a fixed dose of fluoxetine (20 mg) or cognitive psychotherapy in a 16 week trial of patients with dysthymic disorder." | 9.08 | Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. ( Bea, C; Becker, J; Dunner, DL; Hendrickson, H; Lehman, A; Schmaling, KB, 1996) |
| "This study showed the significant and persistent action of fluoxetine on dysthymia." | 9.08 | Controlled efficacy study of fluoxetine in dysthymia. ( Attar-Levy, D; Blin, P; Bouhassira, M; Olié, JP; Poirier, MF; Vanelle, JM, 1997) |
| "In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day." | 9.08 | Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. ( Smeraldi, E, 1998) |
| " The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine." | 5.17 | L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013) |
| "Although some significant psychomotor changes were observed in a subgroup of clinically responsive dysthymic patients, the overall results of this small, nonrandomized, open-label study do not suggest a beneficial psychomotor effect associated with short-term fluoxetine treatment of dysthymia." | 5.14 | Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study. ( Maas, YJ; Sabbe, BG; Schrijvers, D, 2009) |
| " In the intent-to-treat sample, random regression analyses of the Hamilton Rating Scale for Depression (Ham-D; 24-item) and Cornell Dysthymia Rating Scale (CDRS) scores at each visit produced significant time x treatment group interactions favoring the fluoxetine group." | 5.11 | Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005) |
| "A discontinuation syndrome is common after treatment with SSRIs is stopped in patients with dysthymia, and it appears to be more common in patients receiving paroxetine than in those receiving fluoxetine." | 5.10 | Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. ( Bellino, S; Bogetto, F; Patria, L; Revello, RB, 2002) |
| " Although the art of clinical management of dysthymia should be fully grounded in understanding the interpersonal context of depression, we submit that SSRIs such as fluoxetine appear broadly efficacious in areas previously deemed to be the domain of formal psychotherapy." | 5.09 | The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. ( Akiskal, HS; Haykal, RF, 1999) |
| "We studied the effects of a fixed dose of fluoxetine (20 mg) or cognitive psychotherapy in a 16 week trial of patients with dysthymic disorder." | 5.08 | Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. ( Bea, C; Becker, J; Dunner, DL; Hendrickson, H; Lehman, A; Schmaling, KB, 1996) |
| "A group of 23 elderly outpatients with dysthymic disorder participated in a 13-week fluoxetine trial." | 5.08 | Fluoxetine discontinuation in elderly dysthymic patients. ( Devanand, DP; Kim, MK; Nobler, MS, 1997) |
| "This study showed the significant and persistent action of fluoxetine on dysthymia." | 5.08 | Controlled efficacy study of fluoxetine in dysthymia. ( Attar-Levy, D; Blin, P; Bouhassira, M; Olié, JP; Poirier, MF; Vanelle, JM, 1997) |
| "In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day." | 5.08 | Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. ( Smeraldi, E, 1998) |
| "Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals." | 3.72 | Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004) |
| "Patients with dysthymia have been shown to respond to treatment with antidepressant medications, and to some degree to psychotherapy." | 2.70 | Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. ( Batchelder, S; Fedak, M; Hellerstein, DJ; Kreditor, D; Little, SA; Muran, JC; Rosenthal, RN; Samstag, LW; Winston, A, 2001) |
| "Geriatric dysthymia appears to have less associated psychiatric comorbidity and closer links to severe life stresses, particularly medical illnesses, than dysthymia with early-age onset." | 2.40 | Geriatric dysthymia. ( Kocsis, JH, 1998) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bersani, G | 1 |
| Meco, G | 1 |
| Denaro, A | 1 |
| Liberati, D | 1 |
| Colletti, C | 1 |
| Nicolai, R | 1 |
| Bersani, FS | 1 |
| Koverech, A | 1 |
| Schrijvers, D | 1 |
| Maas, YJ | 1 |
| Sabbe, BG | 1 |
| Lewis, CC | 1 |
| Simons, AD | 1 |
| Silva, SG | 1 |
| Rohde, P | 1 |
| Small, DM | 1 |
| Murakami, JL | 1 |
| High, RR | 1 |
| March, JS | 1 |
| Mendhekar, DN | 1 |
| Liappas, IA | 1 |
| Dimopoulos, NP | 1 |
| Mellos, E | 1 |
| Gitsa, OE | 1 |
| Liappas, AI | 1 |
| Rabavilas, AD | 1 |
| Devanand, DP | 2 |
| Nobler, MS | 2 |
| Cheng, J | 1 |
| Turret, N | 1 |
| Pelton, GH | 1 |
| Roose, SP | 1 |
| Sackeim, HA | 1 |
| Simon, NM | 1 |
| Zalta, AK | 1 |
| Worthington, JJ | 1 |
| Hoge, EA | 1 |
| Christian, KM | 1 |
| Stevens, JC | 1 |
| Pollack, MH | 1 |
| Bourgeois, JA | 1 |
| Klein, M | 1 |
| Dunner, DL | 2 |
| Schmaling, KB | 1 |
| Hendrickson, H | 1 |
| Becker, J | 1 |
| Lehman, A | 1 |
| Bea, C | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Kim, MK | 1 |
| Vanelle, JM | 1 |
| Attar-Levy, D | 1 |
| Poirier, MF | 1 |
| Bouhassira, M | 1 |
| Blin, P | 1 |
| Olié, JP | 1 |
| Smeraldi, E | 1 |
| Kocsis, JH | 1 |
| Haykal, RF | 1 |
| Akiskal, HS | 1 |
| Waslick, BD | 1 |
| Walsh, BT | 1 |
| Greenhill, LL | 1 |
| Eilenberg, M | 1 |
| Capasso, L | 1 |
| Lieber, D | 1 |
| Cailleux, N | 1 |
| Marie, I | 1 |
| Chrétien, MH | 1 |
| Noblet, C | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Zaharia, MD | 1 |
| Ravindran, AV | 1 |
| Griffiths, J | 1 |
| Merali, Z | 1 |
| Anisman, H | 1 |
| Hellerstein, DJ | 1 |
| Little, SA | 1 |
| Samstag, LW | 1 |
| Batchelder, S | 1 |
| Muran, JC | 1 |
| Fedak, M | 1 |
| Kreditor, D | 1 |
| Rosenthal, RN | 1 |
| Winston, A | 1 |
| Bogetto, F | 1 |
| Bellino, S | 1 |
| Revello, RB | 1 |
| Patria, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder[NCT01852383] | Phase 4 | 30 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cornell Dysthymia Rating Scale scores from range 0-64. Lower or decreasing scores represent decreased severity and a better outcome, while higher or increasing scores represent more severe depression and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 28.8 |
The research rater completed the 24-item Hamilton Rating Scale for Depression (HAM-D) and documented the scores on each visit. Hamilton Rating Scale for Depression scores range from 0-50 with low scores or decreasing scores representing decreased severity and better outcome, and higher scores or increasing scores representing more severe depressive symptoms and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Screen (0) and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 8 |
The Treatment Emergent Symptom Scale (TESS) documents the presence of common side effects. There are 26 items and the total score range is 0-26. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects. The change in side effect severity scores was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: 0 and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 5.2 |
Maximum duloxetine oral dose (NCT01852383)
Timeframe: Week 0, 1, 2, 4, 6, 8, 10, 12
| Intervention | mg (Mean) |
|---|---|
| Duloxetine | 101 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
2 reviews available for fluoxetine and Dysthymia
| Article | Year |
|---|---|
Geriatric dysthymia.
Topics: Adult; Age Factors; Age of Onset; Aged; Antidepressive Agents; Clinical Trials as Topic; Comorbidity | 1998 |
Treatment of dysthymic disorder.
Topics: Dysthymic Disorder; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors | 1998 |
14 trials available for fluoxetine and Dysthymia
| Article | Year |
|---|---|
L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cognitive Dysfunction; Diagn | 2013 |
Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study.
Topics: Adult; Antidepressive Agents, Second-Generation; Belgium; Case-Control Studies; Dysthymic Disorder; | 2009 |
The role of readiness to change in response to treatment of adolescent depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined | 2009 |
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
Topics: Age Factors; Aged; Aging; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method | 2005 |
Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder.
Topics: Adult; Age of Onset; Anxiety Disorders; Comorbidity; Depression; Dysthymic Disorder; Female; Fluoxet | 2006 |
Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Dysthymic | 1996 |
Fluoxetine discontinuation in elderly dysthymic patients.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Dose-Response Relationship, | 1997 |
Controlled efficacy study of fluoxetine in dysthymia.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Administration Schedule; | 1997 |
Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study.
Topics: Adolescent; Adult; Aged; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 1998 |
The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management.
Topics: Adult; Age of Onset; Aged; Antidepressive Agents, Tricyclic; Cohort Studies; Combined Modality Thera | 1999 |
Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Dysthymic Disorder; Female; Fluoxetine; | 1999 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymi | 2000 |
Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents, Second-Generation; Dysthymic Disorde | 2001 |
Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Dysthymic Disorder; Female; Fluox | 2002 |
5 other studies available for fluoxetine and Dysthymia
| Article | Year |
|---|---|
Fluoxetine-induced breast atrophy.
Topics: Adult; Atrophy; Breast; Dysthymic Disorder; Female; Fluoxetine; Humans; Selective Serotonin Reuptake | 2004 |
Oral transmucosal abuse of transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug A | 2004 |
Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Comorbidity; Dysthymic Disord | 1996 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
[Spontaneous hematoma: thoughts about selective serotonin uptake inhibitors].
Topics: Adenocarcinoma; Breast Neoplasms; Dysthymic Disorder; Ecchymosis; Female; Fluoxetine; Hematoma; Huma | 2000 |